USANA Health Sciences
The 10-second takeaway
For the quarter ended March 31 (Q1), USANA Health Sciences beat expectations on revenues and crushed expectations on earnings per share.
Compared with the prior-year quarter, revenue grew and GAAP earnings per share increased significantly.
Margins increased across the board.
USANA Health Sciences chalked up revenue of $154.1 million. The four analysts polled by S&P Capital IQ predicted revenue of $143.9 million on the same basis. GAAP reported sales were 7.4% higher than the prior-year quarter's $143.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.90. The five earnings estimates compiled by S&P Capital IQ predicted $0.69 per share. GAAP EPS of $0.90 for Q1 were 29% higher than the prior-year quarter's $0.70 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 82.3%, 20 basis points better than the prior-year quarter. Operating margin was 13.5%, 150 basis points better than the prior-year quarter. Net margin was 8.9%, 100 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $155.2 million. On the bottom line, the average EPS estimate is $0.92.
Next year's average estimate for revenue is $623.7 million. The average EPS estimate is $3.67.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 200 members out of 380 rating the stock outperform, and 180 members rating it underperform. Among 126 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give USANA Health Sciences a green thumbs-up, and 79 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on USANA Health Sciences is hold, with an average price target of $41.20.
Over the decades, small-cap stocks like USANA Health Sciences have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.
- Add USANA Health Sciences to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings. He is the co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.